These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 1347102

  • 21. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
    Brakman GG.
    Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
    [Abstract] [Full Text] [Related]

  • 22. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R.
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [Abstract] [Full Text] [Related]

  • 23. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome.
    Rasi V, Ikkala E.
    Br J Haematol; 1990 Nov; 76(3):369-71. PubMed ID: 2124498
    [Abstract] [Full Text] [Related]

  • 24. Inhibitors in congenital coagulation disorders.
    Key NS.
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [Abstract] [Full Text] [Related]

  • 25. Inhibitors in patients with haemophilia A.
    Kreuz W, Ettingshausen CE.
    Thromb Res; 2014 Nov; 134 Suppl 1():S22-6. PubMed ID: 24745722
    [Abstract] [Full Text] [Related]

  • 26. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O, ObsITI study group, ObsITI committee.
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [Abstract] [Full Text] [Related]

  • 27. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C, Patharathienskul D, Suvatte V.
    Southeast Asian J Trop Med Public Health; 1993 Jan; 24 Suppl 1():106-12. PubMed ID: 7886549
    [Abstract] [Full Text] [Related]

  • 28. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.
    Semin Thromb Hemost; 1995 Jan; 21(4):382-9. PubMed ID: 8747701
    [Abstract] [Full Text] [Related]

  • 29. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł.
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [Abstract] [Full Text] [Related]

  • 30. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R, Nemes L, Jimenez-Yuste V, Rusen L, Cid AR, Charnigo RJ, Baumann JA, Smith L, Korth-Bradley JM, Rendo P.
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [Abstract] [Full Text] [Related]

  • 31. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
    Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Kaiml M, Kornhuber B.
    Vox Sang; 1999 Oct; 77 Suppl 1():3-8. PubMed ID: 10529676
    [No Abstract] [Full Text] [Related]

  • 32. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H, Beck EA.
    Acta Haematol; 1980 Oct; 64(1):12-7. PubMed ID: 6774572
    [Abstract] [Full Text] [Related]

  • 33. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
    Knöbl P, Derfler K.
    Vox Sang; 1999 Oct; 77 Suppl 1():57-64. PubMed ID: 10529691
    [Abstract] [Full Text] [Related]

  • 34. The epidemiology of inhibitors in haemophilia A: a systematic review.
    Wight J, Paisley S.
    Haemophilia; 2003 Jul; 9(4):418-35. PubMed ID: 12828678
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
    Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, Blanchette VS, Rivard GE, Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2006 Jan; 12(1):7-18. PubMed ID: 16409170
    [Abstract] [Full Text] [Related]

  • 40. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.
    Mariani G, Ghirardini A, Bellocco R.
    Thromb Haemost; 1994 Jul; 72(1):155-8. PubMed ID: 7974364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.